MAIA Biotechnology, Inc. (MAIA) Raises $695K in Private Placement to Advance Cancer Trial
MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company, has announced a private placement agreement to raise approximately $695,000.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% | |
2. | Renaissance Technologies Jim Simons | 0 | $0 | 0% |
Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$1.50 | 33,333 | $49,999.50 | 1,305,059 | 2025-06-03 | Filing | |
$1.50 | 20,000 | $30,000.00 | 588,218 | 2025-05-08 | Filing | |
$1.50 | 66,666 | $99,999.00 | 1,271,726 | 2025-05-08 | Filing | |
$1.50 | 33,333 | $49,999.50 | 568,218 | 2025-03-03 | Filing | |
$1.50 | 25,000 | $37,500.00 | 1,205,060 | 2025-03-03 | Filing |
No. | Name | Shares | Value | % Port |
---|---|---|---|---|
1. | 1,140,769 | $2,053,384 | 0% | |
2. | 573,398 | $871,565 | 0.21% | |
3. | 222,183 | $400,037 | 0% | |
4. | 103,265 | $185,876 | 0% | |
5. | 15,730 | $28,314 | 0.02% |